Alpha Tau to Participate in Five September Investor Conferences
Alpha Tau Medical (NASDAQ: DRTS), developer of the innovative Alpha DaRT® alpha-radiation cancer therapy, announced CFO Raphi Levy's participation in five investor conferences this September 2025. The Alpha DaRT platform represents a novel approach to solid tumor treatment using localized alpha particle radiotherapy, designed to destroy tumors while preserving healthy tissue.
The conferences include the Citi Biopharma Back to School Summit, H.C. Wainwright Global Investment Conference, Oppenheimer's Targeted Radiopharmaceutical Therapies Summit, RTH & Co Radiopharma Conference, and Lytham Partners Fall Conference. The company expects key milestones and pivotal data from multiple clinical trials in 2025-2026.
Alpha Tau Medical (NASDAQ: DRTS), sviluppatore dell’innovativa terapia oncologica a radiazione alfa Alpha DaRT®, ha annunciato la partecipazione del CFO Raphi Levy a cinque conferenze per investitori nel settembre 2025. La piattaforma Alpha DaRT rappresenta un approccio nuovo al trattamento dei tumori solidi, basato sulla radioterapia con particelle alfa localizzate, progettata per eliminare le neoplasie preservando il tessuto sano.
Le conferenze comprendono il Citi Biopharma Back to School Summit, l’H.C. Wainwright Global Investment Conference, il Targeted Radiopharmaceutical Therapies Summit di Oppenheimer, il RTH & Co Radiopharma Conference e il Lytham Partners Fall Conference. La società prevede traguardi importanti e dati cruciali da diversi trial clinici nel periodo 2025-2026.
Alpha Tau Medical (NASDAQ: DRTS), desarrollador de la innovadora terapia oncológica con radiación alfa Alpha DaRT®, anunció la participación del CFO Raphi Levy en cinco conferencias para inversores en septiembre de 2025. La plataforma Alpha DaRT constituye un enfoque novedoso para el tratamiento de tumores sólidos, empleando radioterapia con partículas alfa localizadas, diseñada para destruir tumores preservando el tejido sano.
Las conferencias incluyen el Citi Biopharma Back to School Summit, el H.C. Wainwright Global Investment Conference, el Targeted Radiopharmaceutical Therapies Summit de Oppenheimer, el RTH & Co Radiopharma Conference y el Lytham Partners Fall Conference. La compañía espera hitos clave y datos decisivos de múltiples ensayos clínicos entre 2025 y 2026.
Alpha Tau Medical (NASDAQ: DRTS)는 혁신적인 알파 방사선 암 치료제 Alpha DaRT®의 개발사로서, 최고재무책임자(CFO) Raphi Levy가 2025년 9월에 다섯 개의 투자자 컨퍼런스에 참가한다고 발표했습니다. Alpha DaRT 플랫폼은 고형암 치료에 대한 새로운 접근법으로, 국소화된 알파 입자 방사선요법을 통해 정상 조직을 보존하면서 종양을 파괴하도록 설계되었습니다.
참가하는 컨퍼런스는 Citi Biopharma Back to School Summit, H.C. Wainwright Global Investment Conference, Oppenheimer's Targeted Radiopharmaceutical Therapies Summit, RTH & Co Radiopharma Conference, 그리고 Lytham Partners Fall Conference입니다. 회사는 2025~2026년 여러 임상시험에서 중요한 이정표와 핵심 데이터를 기대하고 있습니다.
Alpha Tau Medical (NASDAQ: DRTS), développeur de l’innovante thérapie anticancéreuse par radiation alpha Alpha DaRT®, a annoncé la participation du CFO Raphi Levy à cinq conférences investisseurs en septembre 2025. La plateforme Alpha DaRT représente une approche nouvelle du traitement des tumeurs solides, utilisant une radiothérapie aux particules alpha localisées, conçue pour détruire les tumeurs tout en préservant les tissus sains.
Les conférences comprennent le Citi Biopharma Back to School Summit, le H.C. Wainwright Global Investment Conference, le Oppenheimer's Targeted Radiopharmaceutical Therapies Summit, le RTH & Co Radiopharma Conference et le Lytham Partners Fall Conference. La société prévoit des étapes clés et des données cruciales issues de plusieurs essais cliniques en 2025–2026.
Alpha Tau Medical (NASDAQ: DRTS), Entwickler der innovativen Alpha-Strahlentherapie gegen Krebs Alpha DaRT®, gab bekannt, dass CFO Raphi Levy im September 2025 an fünf Investorenkonferenzen teilnehmen wird. Die Alpha DaRT-Plattform stellt einen neuartigen Ansatz zur Behandlung solider Tumoren dar, indem sie lokalisierte Alpha-Partikel-Strahlentherapie einsetzt, um Tumore zu zerstören und gesunde Gewebe zu schonen.
Zu den Konferenzen zählen das Citi Biopharma Back to School Summit, das H.C. Wainwright Global Investment Conference, das Oppenheimer's Targeted Radiopharmaceutical Therapies Summit, das RTH & Co Radiopharma Conference und das Lytham Partners Fall Conference. Das Unternehmen erwartet in den Jahren 2025–2026 wichtige Meilensteine und wegweisende Daten aus mehreren klinischen Studien.
- None.
- None.
JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present and meet investors in the following five investor conferences in September 2025.
The Alpha DaRT platform is a novel approach using localized alpha particle radiotherapy with the goal of destroying solid tumors while sparing surrounding healthy tissue. With broad potential applicability for local tumor control, together with signs of compelling immuno-stimulatory activity, the platform technology is being explored for utilization alone or synergistically with other cancer treatment modalities. Key milestones and pivotal data from multiple clinical trials in different indications are expected in 2025 and 2026.
| Event: | Citi 2025 Biopharma Back to School Summit |
| Format: | 1x1 Meetings |
| Date: | September 2-3, 2025 |
| Location: | Boston, MA |
| Event: | H.C. Wainwright 27th Annual Global Investment Conference |
| Format: | Company Presentation and 1x1 Meetings |
| Date: | September 9, 2025 |
| Time | 3:00 - 3:30pm |
| Location: | New York, NY |
| Event: | Oppenheimer’s Third Annual Targeted Radiopharmaceutical Therapies in Oncology Summit |
| Format: | 1x1 Meetings |
| Date: | September 11, 2025 |
| Location: | New York, NY |
| Event: | RTH & Co / Redburn Atlantic - Radiopharma Landscape Conference |
| Format: | 1x1 Meetings |
| Date: | September 26, 2025 |
| Location: | New York, NY |
| Event: | Lytham Partners Fall 2025 Investor Conference |
| Format: | 1x1 Meetings |
| Date: | September 30, 2025 |
| Location: | Virtual |
Mr. Levy will be available for 1x1 investor meetings at all conferences. Please reach out to your representatives at the respective conference organizers to schedule.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “being,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, including with respect to clinical trials, regulatory approvals and studies, and our treatment goals and applicablility potential, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on form 20-F with the SEC on March 12, 2025, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.
Investor Relations Contact:
FAQ
When is Alpha Tau Medical (DRTS) presenting at the H.C. Wainwright Conference in September 2025?
What is Alpha Tau Medical's (DRTS) Alpha DaRT technology?
When will Alpha Tau Medical (DRTS) release clinical trial data?
Which investor conferences is Alpha Tau Medical (DRTS) attending in September 2025?
